12 September 2017

Invest in Skåne

Hosted by: Invest in Skåne

View session Description
NLSDays 2017 pre-event

MAX IV & ESS tour

10:00 - 14:00Bus Tour to Lund


View session Description

Academic Catwalk

17:00 - 18:15Main Hall

Nordic academic scientists will showcase intriguing research that could be the base for next generation therapies. The presentation will be followed by a short Q&A and is intended to give rise to inspiring discussions.

SmiLe Incubator
Johnson & Johnson Innovation

Hosted by: SmiLe IncubatorCo - Hosted by: Johnson & Johnson Innovation

View session Description

Startup Challenge @ NLSDays

18:30 - 20:00Main Hall

The Startups’ Slam is a pitching competition giving innovative entrepreneurs an opportunity to showcase. Selected companies will present their innovative technologies to a selected jury representing life science executives from industry and finance.

13 September 2017


Hosted by: SwedenBIOCo - Hosted by: bionordic

Olivier Duchamp - Managing Director - NLSDays, CEO - Bionordic Services Jonas Ekstrand - Managing Director - SwedenBIO Mikael Dolsten - President Worldwide Research and Development and EVP - Pfizer

Lund University Diabetes Center
LU Innovation
Novo Nordisk

Hosted by: Lund University Diabetes CenterCo - Hosted by: LU Innovation, Novo Nordisk, Sanofi

View session Description

Super Session 1 – Diabetes

09:30 - 10:45Plenary Room - Main Hall

The diabetes session will focus on disruptive new solutions and future diabetes treatment options. Special focus will be on recent developments , where closed loop systems and ultrafast acting insulins will be game changers for insulin treated diabetes patients, especially those with unstable blood glucose.

Søren Bregenholt - Corporate VP and Head of External Innovation - Novo Nordisk Charlotte Ling - Professor, Lund University Uli Wendt - Head External Innovation and Alliance Management, Global Diabetes Division, R&D - Sanofi

Business Region Göteborg
Invest in Skåne

Hosted by: Business Region GöteborgCo - Hosted by: Invest in Skåne

View session Description

Super Session 2 – Regenerative Medicine

11:15 - 12:30Plenary Room - Main Hall

This supersession will focus on a specific field of regenerative medicine, Gene Therapy. The possibility to replace defective genes in a patient’s cells with healthy ones using viral vectors and gene editing technologies, opens up the potential to treat or prevent numerous diseases which currently lack successful treatment. Although most gene therapies are still in an experimental stage, several examples have recently been successfully translated into clinical practice and products with regulatory approval. This session will discuss the diverse challenges involved in the translation of gene therapies to clinic and market, and highlight some successful examples.

Steffen Thirstrup - Director Regulatory Advisory Board - NDA Reg

Arthur D. Little

Hosted by: DNBCo - Hosted by: Arthur D. Little

View session Description
A new mechanism to fund the timely execution of lower-priority clinical trials

Super Session 4 – Financing of Phase 3 Studies

15:45 - 17:00Plenary Room - Main Hall

Some biopharma companies have built pipelines that offer more development opportunities than their resources allow them to pursue. Promising clinical trials may be moved down the priority list and their execution delayed – resulting in decline of asset value against a fixed patent expiration date. One potential solution is to package complementary trials and bring them into collaboration with investors, CROs or other organizations and fund the execution of these trials outside the biopharma company. There are several potential advantages of this approach. But this session will also reflect upon questions like: What would be the primary driving forces for different parties to engage in this type of collaborations? Are there also complications with the phenomenon? How does the excess of promising assets with large biopharma companies affect other parts of the life science ecosystem?

Moderator: Ulrica Sehlstedt - Partner - Arthur D. Little

Jo Sawyer - Head of External Partnerships - Novartis

14 September 2017


Hosted by: SwedenBIOCo - Hosted by: Covance

View session Description
Service providers as research power houses

Super Session 5 – Preclinical & Clinical Methodological Advancements

08:00 - 09:15Plenary Room - Main Hall

Many of the service providers in life science R&D have their own research. They provide much more than just an extra pair of hands and they spend high amounts on in house development of their services. With this super session, we will highlight their efforts and importance for the life science ecosystem where many of the companies are small and source for the latest technologies for their research and development.


Bristol-Myers Squibb

Hosted by: AbbVieCo - Hosted by: Bristol-Myers Squibb

Moderator: Marianne Larsson - Innovation Director - Innovation Skåne

Amir Hefni - Country Manager - Bristol-Myers Squibb

Oslo Cancer Cluster

Hosted by: Oslo Cancer ClusterCo - Hosted by: DNB

View session Description
Advancing Cancer Immunotherapy by novel partnerships, bugs and bytes

Super Session 7 – Transformative Oncology

11:15 - 12:30Plenary Room - Main Hall

The session gathers a group of experts with complementary expertise to present and discuss recent approaches in Cancer Immunotherapy. Tremendous scientific progress resulted in real clinical breakthroughs and a growing number of cancers are now successfully treated with immunotherapy. However, many challenges remain and for tackling these collaborations among various disciplines is essential. A set of compact presentations will highlight how players from pharma, biotech and academia advance the field and what we can learn from microbiologists and machine learning experts.

Moderator: Benedicte Bakke - Senior Advisor, International Healthcare - DNB

Khatereh Ahmadi - Executive Director, Oncology Search and Evaluation Lead - MSD Per Norlèn - CEO -Alligator Bioscience Stefan Ries - Global Head of External Innovation, Oncology Discovery - pRED Roche Henrik Winther - Senior Vice President, Precision Diagnostics - Immunovia

Life Science Nation

Hosted by: Life Science NationCo - Hosted by: Novo

View session Description
Best Practices for Identifying Capital in the Global Life Science Arena

Super Session 8 – Redefining Early Stage Investments

14:00 - 15:15Plenary Room - Main Hall

Early Stage Investments session provides a top-to-bottom master class on outbound global fundraising. Topics to be covered include the changing investor landscape, new categories of life science investors, and how to organize and execute a successful roadshow. It will bring you step-by-step through the processes of positioning, marketing collateral, website creation, branding & messaging, and how to reach out to a list of global investors.